Humana Surges 16% to 52-Week High as 95% of Members Land in 4-Star Plans
HUM has more than doubled off its 52-week low of $163.11.
Summary
Humana's 2027 Medicare Advantage Star Ratings came in strong, with 95% of members in plans rated 4 stars or above and 42% in 4.5-star or higher plans. The company exceeded its top-quartile goal and added 11 contracts at or above 4.0 stars versus last year. Shares jumped 16% in premarket trading to $449.41, a new 52-week high, as the market prices in the 2028 earnings benefit from these ratings. The company also disclosed it expects a one-time 2028 benefit to fund investments and shareholder returns, with details to come. This follows the earlier BusinessWire release on the same ratings, but the stock move and capital strategy disclosure are new. The reaffirmed 2026 EPS guidance of at least $9 remains below the $9.15 consensus, but the ratings improvement is the dominant driver today.
At the time of this announcement, HUM was trading at $433.89 on NYSE in the Life Sciences sector, with a market capitalization of approximately $52.1B. The 52-week trading range was $163.11 to $456.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.